TITLE:
Study Evaluating the Safety and Efficacy of Etanercept in Patients With Idiopathic Pulmonary Fibrosis

CONDITION:
Pulmonary Fibrosis

INTERVENTION:
Etanercept

SUMMARY:

      The objective of the study is to evaluate the safety and efficacy of etanercept in
      comparison with placebo in a double-blind, parallel, randomized fashion in subjects with
      idiopathic pulmonary fibrosis (IPF) who failed previous therapy. The treatment period will
      be up to 1 year. The primary objective is evaluation of safety and efficacy. Secondary: The
      secondary objective is to evaluate quality of life (QoL) and pharmacokinetics (PK).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 40 Years to 80 Years
Criteria:

        Inclusion Criteria:

          -  Diagnosis of IPF based on American Thoracic Society (ATS) guidelines

        Exclusion Criteria:

          -  Subjects with end-stage

          -  Previous treatment with etanercept or other TNF antagonists (eg, a TNF monoclonal
             antibody or a soluble TNF-receptor)

          -  Receipt of any investigational drug or biological agent within 4 weeks of screening
             visit
      
